Company
Incannex Healthcare Inc
NASDAQ:IXHL
Incannex Healthcare Inc is a clinical-stage biopharmaceutical company leading the way in developing combination therapeutics that target underlying biological pathways associated with chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. The company's strategy is to advance novel therapies by leveraging evidence-based innovation with the potential to transform the lives of people suffering from these conditions.
55 stories · page 1 of 3
Incannex Healthcare targeting $120 billion global addressable market with cannabinoid and psychedelic therapeutics
The company's point of difference is its hybrid model, as a major player in two emerging global markets – cannabinoid research and psychedelics. It was the first company to investigate psychedelics that was listed on the ASX and it has seen